45 filings
Page 2 of 3
8-K
lvadrzd5 hodkuql
19 Aug 22
Kymera Announces $150 Million Private Placement Equity Financing
7:59am
8-K
7fg9pvmafrpbk1bjd2o
9 Aug 22
Kymera Therapeutics Announces Second Quarter 2022 Financial Results and Provides a Business Update
7:10am
8-K
05wbbemj fq
8 Jul 22
Departure of Directors or Certain Officers
7:45am
8-K
z1p3 qqepr5pbgam
16 Jun 22
Submission of Matters to a Vote of Security Holders
4:06pm
8-K
mgia066hqnghv
3 May 22
Kymera Therapeutics Announces First Quarter 2022 Financial Results and Provides a Business Update
7:10am
8-K
4ffu6h
11 Apr 22
Departure of Directors or Certain Officers
4:16pm
8-K
dmc wg90n3dip8h
24 Feb 22
Kymera Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides a Business Update
7:10am
8-K
8hk 03mvdp
18 Jan 22
Departure of Directors or Certain Officers
4:06pm
8-K
b3h5cipovj
27 Dec 21
Entry into a Material Definitive Agreement
4:09pm
8-K
8bwdl4qjzyt4jm3
16 Dec 21
Other Events
7:12am
8-K
8yzd2 aph0g
10 Nov 21
Kymera Therapeutics Announces Third Quarter 2021 Financial Results and Provides a Business Update
7:16am
8-K
wysbwla6h8gn5fb hyg
27 Oct 21
Regulation FD Disclosure
9:02am
8-K
0r2b44
16 Sep 21
Departure of Directors or Certain Officers
4:02pm
8-K
7wceqsh
6 Aug 21
Kymera Therapeutics Announces Second Quarter 2021 Financial Results and Provides a Business Update
7:10am
8-K
knejnnytr 2afzud
28 Jun 21
Kymera Therapeutics Announces Positive Interim Results from Single Ascending Dose Phase 1 Trial of KT-474 Demonstrating Degrader Proof-of-Mechanism
7:46am
8-K
sqi7f8bpfcyql 9lus
17 Jun 21
Submission of Matters to a Vote of Security Holders
4:41pm
8-K
074j8l
6 May 21
Kymera Therapeutics Announces First Quarter 2021 Financial Results and Provides a Business Update
7:10am
8-K
2aut 58tj
16 Mar 21
Departure of Directors or Certain Officers
4:15pm
8-K
16mx2ecs
11 Mar 21
Kymera Therapeutics Announces Fourth Quarter and Full Year 2020 Financial
7:09am
8-K
zrqshh
2 Mar 21
KT-474 is the first IRAK4 degrader, and first heterobifunctional small molecule protein degrader outside of oncology, to enter clinical development
7:15am